Vaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Average PT from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has received a consensus rating of "Buy" from the ten research firms that are covering the company, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $136.50.

Several equities research analysts have recently commented on PCVX shares. Cantor Fitzgerald began coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating for the company. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Needham & Company LLC reissued a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PCVX. Voya Investment Management LLC raised its holdings in Vaxcyte by 1.7% in the first quarter. Voya Investment Management LLC now owns 306,729 shares of the company's stock worth $11,582,000 after purchasing an additional 5,169 shares during the period. Rhumbline Advisers increased its position in shares of Vaxcyte by 5.5% in the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after buying an additional 9,416 shares in the last quarter. Strs Ohio bought a new stake in shares of Vaxcyte in the 1st quarter valued at $627,000. Intech Investment Management LLC raised its stake in Vaxcyte by 44.3% during the 1st quarter. Intech Investment Management LLC now owns 89,212 shares of the company's stock worth $3,369,000 after buying an additional 27,384 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock worth $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Down 0.1%

NASDAQ:PCVX traded down $0.04 during mid-day trading on Monday, reaching $33.24. 474,884 shares of the company were exchanged, compared to its average volume of 1,467,234. The stock has a market cap of $4.29 billion, a PE ratio of -8.33 and a beta of 1.19. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $121.06. The company has a fifty day moving average of $33.34 and a 200 day moving average of $58.02.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the company earned ($0.85) EPS. On average, equities research analysts anticipate that Vaxcyte will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.